Olema Pharmaceuticals, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
780 BRANNAN STREET, SAN FRANCISCO, CA, 94103
Mailing Address
780 BRANNAN STREET, SAN FRANCISCO, CA, 94103
Phone
(415) 651-3316
Fiscal Year End
1231
EIN
300409740
Financial Overview
FY2025
$533.43M
Total Assets
$478.56M
Stockholders' Equity
$139.48M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G Passive beneficial ownership (>5%) | March 20, 2026 | View on SEC |
| 10-K Annual financial report | March 16, 2026 | View on SEC |
| 8-K Current report of material events | March 16, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 6, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 3 Initial insider ownership report | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
Annual Reports
10-K
March 16, 2026
- Lead drug candidate palazestrant is in pivotal Phase 3 trials (OPERA-01 & OPERA-02) with potential NDA submissions in 2027 and 2029.
- Strategic collaborations with Novartis and Pfizer for palazestrant provide external resources and validation.
Insider Trading
STRONG SELL
6 insiders
23 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.